Hostname: page-component-7c8c6479df-ph5wq Total loading time: 0 Render date: 2024-03-29T05:09:36.359Z Has data issue: false hasContentIssue false

PW01-28 - Asenapine as Adjunctive Treatment For Bipolar Mania: A Placebo-controlled 12-week Study and 40-week Extension

Published online by Cambridge University Press:  17 April 2020

J. Calabrese
Affiliation:
Case Western Reserve University School of Medicine, Cleveland, OH, USA
L. Stet
Affiliation:
Schering Corp., a Division of Merck & Co., Summit, NJ, USA
H. Kotari
Affiliation:
Schering Corp., a Division of Merck & Co., Summit, NJ, USA
J. Zhao
Affiliation:
Schering Corp., a Division of Merck & Co., Summit, NJ, USA
A. Kouassi
Affiliation:
Schering Corp., a Division of Merck & Co., Summit, NJ, USA
A. Szegedi
Affiliation:
Schering Corp., a Division of Merck & Co., Summit, NJ, USA
J. Panagides
Affiliation:
Schering Corp., a Division of Merck & Co., Summit, NJ, USA

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Objectives

Asenapine is indicated in adults for acute treatment of schizophrenia and bipolar I disorder. We describe the efficacy and tolerability of adjunctive asenapine in bipolar patients showing incomplete response to lithium or valproate monotherapy.

Methods

In a 12-week core study, patients were randomized to flexible-dose asenapine (5 or 10 mg BID) or placebo as an adjunct to continued mood stabilizer therapy. Patients completing the core study without protocol violations could enter a 40-week extension. Changes from core study baseline on the Young Mania Rating Scale (YMRS) and Montgomery-Asberg Depression Rating Scale (MADRS) total scores were assessed at week 3 of the core study and at week 52 in the extension. Efficacy in the core study was assessed using ANCOVA with LOCF to impute missing data. The extension was not powered for statistical comparisons; descriptive statistics were employed.

Results

The intent-to-treat population comprised 318 patients (asenapine, 155; placebo, 163) in the core study and 71 (38; 33) in the extension. Mean±SD changes at week 3 with asenapine and placebo, respectively, were -9.7±10.1 versus -7.7±9.6 (P=0.0257) on YMRS and -2.8±7.2 versus -2.2±6.8 (P=0.3684) on MADRS. Mean±SD changes at week 52 with asenapine and placebo were -17.2±13.7 versus -19.7±11.8 on YMRS and -3.3±9.8 versus -3.9±7.7 on MADRS. The incidence of treatment-emergent AEs with asenapine and placebo was 73% and 69% in the core study, 78% and 69% in the extension.

Conclusions

Asenapine was effective as an adjunct to mood stabilizer in bipolar I disorder and was well tolerated.

Type
Affective disorders / Unipolar depression / Bipolar disorder
Copyright
Copyright © European Psychiatric Association 2010
Submit a response

Comments

No Comments have been published for this article.